Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FASN | P49327 | 13/20 | 0.39 |
| ▸ | PDE2A | O00408 | 2/20 | 0.39 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | MAPK7 | Q13164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3878552 | 0.95 | CYP3A4 (0.41) | FASNEPHX2CYP3A4CYP2C9SLC9A1 | |
| SCHEMBL3879180 | 0.85 | FASN (0.42) | FASNPDE2APDE3AEPHX2KCNH2 | |
| SCHEMBL3880890 | 0.83 | PDE2A (0.42) | PDE2ACYP3A4CYP2C9CYP2C19ALDH1A1 | |
| SCHEMBL3879718 | 0.83 | NOS1 (0.40) | FASNCYP3A4CYP2C9CYP2C19KCNH2 | |
| SCHEMBL3880580 | 0.83 | UBE2M (0.42) | CYP3A4CYP2C9SLC9A1CYP2C19ALDH1A1 | |
| SCHEMBL3879365 | 0.83 | UBE2M (0.53) | CYP3A4CYP2C9CYP2C19ALDH1A1MAPK7 | |
| SCHEMBL3879091 | 0.82 | UBE2M (0.41) | CYP3A4CYP2C9SLC9A1CYP2C19ALDH1A1 | |
| SCHEMBL3883230 | 0.82 | GRM5 (0.32) | — | |
| SCHEMBL3880002 | 0.81 | PARP1 (0.36) | CYP3A4 | |
| SCHEMBL3878546 | 0.80 | L3MBTL3 (0.43) | FASNEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1858900-B1 | FUSED THIAZOLE DERIVATIVES HAVING AFFINITY FOR THE HISTAMINE H3 RECEPTOR | GLAXO GROUP LTD (GB) | 2009-01-07 | — | — | EP | claimed |
| US-20080161289-A1 | Fused Thiazole Derivatives Having Affinity for the Histamine H3 Receptor | GLAXO GROUP LIMITED | 2008-07-03 | — | — | US | claimed |
| EP-1858900-B1 | FUSED THIAZOLE DERIVATIVES HAVING AFFINITY FOR THE HISTAMINE H3 RECEPTOR | GLAXO GROUP LTD (GB) | 2009-01-07 | — | — | EP | disclosed |
| US-20080161289-A1 | Fused Thiazole Derivatives Having Affinity for the Histamine H3 Receptor | GLAXO GROUP LIMITED | 2008-07-03 | — | — | US | disclosed |
| EP-1858900-A1 | FUSED THIAZOLE DERIVATIVES HAVING AFFINITY FOR THE HISTAMINE H3 RECEPTOR | GLAXO GROUP LIMITED (GB) | 2007-11-28 | — | — | EP | disclosed |
| WO-2006097691-A1 | FUSED THIAZOLE DERIVATIVES HAVING AFFINITY FOR THE HISTAMINE H3 RECEPTOR | GLAXO GROUP LIMITED (GB) | 2006-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161289-A1 | Fused Thiazole Derivatives Having Affinity for the Histamine H3 Receptor | HRH3, HRH4, HRH2 | FASN 4538/4885PDE2A 4486/4885PDE3A 4395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.